[25-NSE] Turnstone Biologics Corp. SEC Filing
Turnstone Biologics Corp. submitted a Form 25 notification concerning the removal of its Common Stock from listing and/or registration under Section 12(b) of the Securities Exchange Act. The filing identifies the issuer, the Nasdaq Stock Market LLC as the exchange, the issuer's address and telephone number, and Commission File Number 001-41747.
Nasdaq certifies it has reasonable grounds to file the Form 25 and includes statements of compliance with 17 CFR 240.12d2-2(b) and 12d2-2(c). The notice is signed by Jennifer Fainer, CDO Analyst on 2025-08-11. The filing does not state an effective delisting date nor clearly indicate which specific rule provision box was marked.
Turnstone Biologics Corp. ha presentato una notifica Form 25 relativa alla rimozione delle sue Azioni Ordinarie dalla quotazione e/o registrazione ai sensi della Sezione 12(b) del Securities Exchange Act. Il deposito indica l'emittente, la Nasdaq Stock Market LLC come mercato, l'indirizzo e il numero di telefono dell'emittente e il Commission File Number 001-41747.
Nasdaq certifica di avere ragionevoli motivi per presentare il Form 25 e include dichiarazioni di conformità a 17 CFR 240.12d2-2(b) e 12d2-2(c). La comunicazione è firmata da Jennifer Fainer, CDO Analyst in data 2025-08-11. Il deposito non indica una data effettiva di delisting né specifica chiaramente quale casella relativa alla disposizione normativa sia stata selezionata.
Turnstone Biologics Corp. presentó una notificación Form 25 relativa a la remoción de sus Acciones Ordinarias de la cotización y/o del registro conforme a la Sección 12(b) del Securities Exchange Act. La presentación identifica al emisor, a la Nasdaq Stock Market LLC como bolsa, la dirección y el número de teléfono del emisor, y el Commission File Number 001-41747.
Nasdaq certifica que tiene motivos razonables para presentar el Form 25 e incluye declaraciones de cumplimiento con 17 CFR 240.12d2-2(b) y 12d2-2(c). La notificación está firmada por Jennifer Fainer, CDO Analyst con fecha 2025-08-11. La presentación no indica una fecha efectiva de exclusión de cotización ni aclara cuál casilla de la disposición normativa fue marcada.
Turnstone Biologics Corp.는 보통주(Common Stock)의 상장 및/또는 등록(Section 12(b)) 삭제와 관련한 Form 25 통지서를 제출했습니다. 제출서에는 발행인, 거래소로서의 Nasdaq Stock Market LLC, 발행인의 주소 및 전화번호, 그리고 Commission File Number 001-41747가 기재되어 있습니다.
Nasdaq는 Form 25 제출에 합리적 근거가 있음을 인증하며 17 CFR 240.12d2-2(b) 및 12d2-2(c) 준수를 명시하는 진술을 포함했습니다. 통지는 2025-08-11자에 Jennifer Fainer, CDO Analyst의 서명이 되어 있습니다. 제출서에는 효력 있는 상장폐지 날짜가 명시되어 있지 않으며, 어떤 특정 규정 항목란이 표시되었는지도 명확히 기재되어 있지 않습니다.
Turnstone Biologics Corp. a déposé une notification Form 25 concernant le retrait de ses Actions Ordinaires de la cotation et/ou de l'enregistrement en vertu de la Section 12(b) du Securities Exchange Act. le dépôt identifie l'émetteur, la Nasdaq Stock Market LLC comme marché, l'adresse et le numéro de téléphone de l'émetteur, ainsi que le Commission File Number 001-41747.
Nasdaq certifie disposer de motifs raisonnables pour déposer le Form 25 et inclut des déclarations de conformité aux 17 CFR 240.12d2-2(b) et 12d2-2(c). L'avis est signé par Jennifer Fainer, CDO Analyst en date du 2025-08-11. Le dépôt n'indique pas de date effective de radiation ni ne précise clairement quelle case liée à la disposition réglementaire a été cochée.
Turnstone Biologics Corp. hat eine Form-25-Mitteilung bezüglich der Entfernung seiner Stammaktien aus der Notierung und/oder Registrierung nach Abschnitt 12(b) des Securities Exchange Act eingereicht. Die Einreichung nennt den Emittenten, die Nasdaq Stock Market LLC als Börse, die Adresse und Telefonnummer des Emittenten sowie die Commission File Number 001-41747.
Nasdaq bestätigt, dass hinreichende Gründe für die Einreichung der Form 25 vorliegen, und enthält Erklärungen zur Einhaltung von 17 CFR 240.12d2-2(b) und 12d2-2(c). Die Mitteilung ist am 2025-08-11 von Jennifer Fainer, CDO Analyst unterzeichnet. Die Einreichung nennt kein wirksames Delisting-Datum und gibt nicht eindeutig an, welches Regelkästchen markiert wurde.
- Nasdaq certifies it has reasonable grounds to file the Form 25 and asserts compliance with applicable rules
- Form 25 is executed and signed by a Nasdaq representative (Jennifer Fainer, CDO Analyst) on 2025-08-11
- Filing includes clear issuer identification (Turnstone Biologics Corp.), exchange (Nasdaq), address, telephone number, and Commission File Number 001-41747
- Form 25 notifies removal of Turnstone Biologics Corp.'s common stock from Nasdaq listing/registration
- No effective delisting date is stated in the filing, leaving timing unclear
- The filing does not explicitly show which rule provision box was marked among the listed 17 CFR citations
Insights
TL;DR: Form 25 filed for Turnstone Biologics signals Nasdaq removal of its common stock; filing confirms compliance but omits an effective date.
The filing is a formal notification under Section 12(b) that Turnstone Biologics Corp.'s common stock will be removed from listing and/or registration. Nasdaq's certification that it has reasonable grounds and the cross-reference to 17 CFR 240.12d2-2(b) and 12d2-2(c) indicate the exchange and issuer represent compliance with procedural requirements. The form is signed by a Nasdaq representative on 2025-08-11. The absence of an effective delisting date and no explicit box selection for the rule provision reduce clarity for shareholders and market participants assessing timing and immediate impacts.
TL;DR: The Form 25 is properly executed and certifies procedural compliance but lacks key timing details investors need.
From a governance perspective, the filing documents that Nasdaq and the issuer have followed the exchange's procedural requirements for removing a class of securities from listing/registration. The issuer, exchange, and signing official are identified, which supports regulatory traceability. However, the filing does not provide the effective date of removal or explicitly indicate which specific rule selection was checked, limiting transparency about when listing termination takes effect and under which precise statutory basis the delisting proceeds.
Turnstone Biologics Corp. ha presentato una notifica Form 25 relativa alla rimozione delle sue Azioni Ordinarie dalla quotazione e/o registrazione ai sensi della Sezione 12(b) del Securities Exchange Act. Il deposito indica l'emittente, la Nasdaq Stock Market LLC come mercato, l'indirizzo e il numero di telefono dell'emittente e il Commission File Number 001-41747.
Nasdaq certifica di avere ragionevoli motivi per presentare il Form 25 e include dichiarazioni di conformità a 17 CFR 240.12d2-2(b) e 12d2-2(c). La comunicazione è firmata da Jennifer Fainer, CDO Analyst in data 2025-08-11. Il deposito non indica una data effettiva di delisting né specifica chiaramente quale casella relativa alla disposizione normativa sia stata selezionata.
Turnstone Biologics Corp. presentó una notificación Form 25 relativa a la remoción de sus Acciones Ordinarias de la cotización y/o del registro conforme a la Sección 12(b) del Securities Exchange Act. La presentación identifica al emisor, a la Nasdaq Stock Market LLC como bolsa, la dirección y el número de teléfono del emisor, y el Commission File Number 001-41747.
Nasdaq certifica que tiene motivos razonables para presentar el Form 25 e incluye declaraciones de cumplimiento con 17 CFR 240.12d2-2(b) y 12d2-2(c). La notificación está firmada por Jennifer Fainer, CDO Analyst con fecha 2025-08-11. La presentación no indica una fecha efectiva de exclusión de cotización ni aclara cuál casilla de la disposición normativa fue marcada.
Turnstone Biologics Corp.는 보통주(Common Stock)의 상장 및/또는 등록(Section 12(b)) 삭제와 관련한 Form 25 통지서를 제출했습니다. 제출서에는 발행인, 거래소로서의 Nasdaq Stock Market LLC, 발행인의 주소 및 전화번호, 그리고 Commission File Number 001-41747가 기재되어 있습니다.
Nasdaq는 Form 25 제출에 합리적 근거가 있음을 인증하며 17 CFR 240.12d2-2(b) 및 12d2-2(c) 준수를 명시하는 진술을 포함했습니다. 통지는 2025-08-11자에 Jennifer Fainer, CDO Analyst의 서명이 되어 있습니다. 제출서에는 효력 있는 상장폐지 날짜가 명시되어 있지 않으며, 어떤 특정 규정 항목란이 표시되었는지도 명확히 기재되어 있지 않습니다.
Turnstone Biologics Corp. a déposé une notification Form 25 concernant le retrait de ses Actions Ordinaires de la cotation et/ou de l'enregistrement en vertu de la Section 12(b) du Securities Exchange Act. le dépôt identifie l'émetteur, la Nasdaq Stock Market LLC comme marché, l'adresse et le numéro de téléphone de l'émetteur, ainsi que le Commission File Number 001-41747.
Nasdaq certifie disposer de motifs raisonnables pour déposer le Form 25 et inclut des déclarations de conformité aux 17 CFR 240.12d2-2(b) et 12d2-2(c). L'avis est signé par Jennifer Fainer, CDO Analyst en date du 2025-08-11. Le dépôt n'indique pas de date effective de radiation ni ne précise clairement quelle case liée à la disposition réglementaire a été cochée.
Turnstone Biologics Corp. hat eine Form-25-Mitteilung bezüglich der Entfernung seiner Stammaktien aus der Notierung und/oder Registrierung nach Abschnitt 12(b) des Securities Exchange Act eingereicht. Die Einreichung nennt den Emittenten, die Nasdaq Stock Market LLC als Börse, die Adresse und Telefonnummer des Emittenten sowie die Commission File Number 001-41747.
Nasdaq bestätigt, dass hinreichende Gründe für die Einreichung der Form 25 vorliegen, und enthält Erklärungen zur Einhaltung von 17 CFR 240.12d2-2(b) und 12d2-2(c). Die Mitteilung ist am 2025-08-11 von Jennifer Fainer, CDO Analyst unterzeichnet. Die Einreichung nennt kein wirksames Delisting-Datum und gibt nicht eindeutig an, welches Regelkästchen markiert wurde.
FAQ
What action does the Form 25 for Turnstone Biologics (TSBX) report?
Who filed or certified the Form 25 for TSBX?
What class of securities is affected for Turnstone Biologics (TSBX)?
Does the Form 25 state when the delisting becomes effective?
Which regulatory provisions are referenced in the filing?
